Russian Scientists Extract "Brain-Repair Sponge" from Jellyfish, Bringing New Hope for Craniocerebral Injuries
Release time:
2026-09-04
Recently, a research team from Don State Technical University (DSTU) in Russia published a breakthrough study in the International Journal of Molecular Sciences: they developed a novel biomaterial based on collagen from the Azov Sea brown-rooted jellyfish (Rhizostoma pulmo) for the protection and repair of brain cells after craniocerebral injury. This study not only offers a new approach to neuroprotection but also transforms the environmental problem of jellyfish overpopulation into a high-value-added medical resource.

Craniocerebral Injury: A Clinical Gap Awaiting Filling
After craniocerebral injury, brain cells undergo severe inflammatory responses and oxidative stress, which can even lead to neuronal death. Hydrogen sulfide (H₂S) is a gaseous molecule naturally synthesized in neural tissues and has well-defined neuroprotective effects; however, its levels drop sharply after injury, triggering a cascade of pathological changes. According to Stanislav Rodkin, head of the laboratory "Medical Digital Images Based on Foundational Models" at DSTU and project leader, about 600,000 people in Russia suffer craniocerebral injuries each year, with many facing death or severe neurological sequelae. Yet, there is currently no clinically validated neuroprotective drug that can effectively mitigate trauma-induced damage to brain cells.
Jellyfish Collagen: A Purer Medical Raw Material
Compared with traditional animal-derived collagen, jellyfish-derived collagen offers significant advantages: higher purity, lower levels of bacterial and metabolic by-products, and greater structural stability, making it a highly promising medical raw material. The research team has mastered the technology to extract high-quality collagen from the brown-rooted jellyfish. This collagen is a natural "structural protein" that constitutes the extracellular matrix of tissues and can be processed into various forms—from soft hydrogels to porous scaffolds—providing an ideal foundation for clinical translation.
"Sponge" Sustained-Release of Hydrogen Sulfide, Dual Mechanisms for Brain Protection
The researchers prepared the extracted collagen into soft, porous matrix scaffolds, whose structure resembles a thin sponge and can maintain the structural integrity of damaged brain tissue. Subsequently, they adopted a sodium thiosulfate (Na₂S₂O₃) impregnation strategy to ensure sustained, slow release of hydrogen sulfide, compensating for the endogenous H₂S deficiency after injury. This novel collagen-based biomaterial thus achieves "dual protection": the collagen matrix provides physical support, while hydrogen sulfide exerts neuroprotective functions, helping to maintain neuronal activity and reduce pathological severity.
Experiments showed that after implanting this matrix into models of severe craniocerebral injury, pathological changes in damaged neural tissues were markedly alleviated, and neuroprotective effects were significant. The team has confirmed that this collagen has good biosafety for neural cells and can be reliably produced with maintained high purity.
Turning Waste into Treasure, with Promising Prospects
Rodkin noted that this study also converts the environmental problem caused by overpopulation of the Azov Sea brown-rooted jellyfish into a source of modern biomedical materials, achieving "waste-to-wealth." Currently, further research is needed to bring this material to clinical application, but the scientific and technological foundations have been laid. This work was supported by the Russian Science Foundation and is expected to offer new therapeutic options for patients with craniocerebral injuries in the future.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.